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http://dx.doi.org/10.1016/j.gmbhs.2Abstract Type 2 diabetes is a multifactorial and polygenic disease that involves insulin resis-
tance and impaired glucose induced insulin release. Besides environmental factors, the influ-
ence of genetic changes also drives the susceptibility of the disease. One such attractive
candidate gene influencing the glucose metabolism is the gene encoding for protein tyrosine
phosphatase 1B (PTPN1), located on the chromosome 20. The gene product is negatively regu-
lating the insulin signaling by dephosphorylating the phosphotyrosine residues of the insulin
receptor kinase activation segment. This study examined the association between one of
the allelic polymorphisms (1023C/A) in PTPN1 gene with type 2 diabetes in the local popula-
tion of Thanjavur, India. Genotypic analysis was performed on 96 diabetic and 96 non-diabetic
patients using polymerase chain reactionebased restriction fragment length polymorphism.
The frequency of allele A in the homozygous form of 1023C>A polymorphism was found to
be lesser (19%) when compared with the control population. In the body mass index (BMI)-
based classification, the homozygous A allele was absent in case participants with BMIs lower
than 30 but it was present in four of the controls with variant allele. Chi square were used to
determine out the significant association of the polymorphism with the disease. There was no
statistical significance obtained for the studied population; the result may be validated by
analyzing larger sample size in the future.
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Type 2 diabetes is a multifactorial and polygenic disease
that involves insulin resistance and impaired glucose
induced insulin release. Type 2 diabetes is a metabolicr@gmail.com (D. Somasekharan).
an Genomic Medicine and Bioma
012.09.002disorder with environmental and genetic components
characterized by insulin resistance and pancreatic b cell
dysfunction; it is also a leading cause of morbidity and
mortality worldwide.1 Diabetes mellitus has reached
epidemic proportions worldwide as we enter the newrker Society. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 PCR amplification products of the region to analyze
1023C>A polymorphism. Lane 1 PUC 19 DNA/MspI digest.
Lanes 2e14 Amplified samples. Lane 10 No amplification. Lane
15 negative control. PCR Z polymerase chain reaction.
PTPN1 polymorphism in diabetes 95millennium. The World Health Organization (WHO) has
commented there is an apparent epidemic of diabetes
strongly related to lifestyle and economic change. Over the
next decade, the projected number will exceed 200
million.2 Most people will have type 2 diabetes, and all are
at risk of the development of complications. The preva-
lence of type 2 diabetes is increasing both in United States
and worldwide. The increase in prevalence of type 2 dia-
betes is owed in part to a decrease in mortality and in part
due to the increased incidence of obesity. Prevalence of
type 2 diabetes had been estimated at 4% for the world
population in 1995, and is expected to rise to 5.4% by 2025.2
In the United States, the prevalence of diagnosed cases of
type 2 diabetes is expected to increase from 135 million in
1995 to 300 million by 2025.2
India is often referred as the “diabetes capital of the
world” due to the alarming increase in the diabetic pop-
ulation.3 In large cities in North and South India, as well as
a national study in large metropolis and industrial pop-
ulation, diabetes prevalence among adults (20 years) has
ranged from 8%e15%. A study from Kashmir in adults older
than 40 years reported a low prevalence of 4.25%, but
a nationwide study of more than 21,000 participants from
big and small cities in India also reported a lower preva-
lence of diabetes as compared with the studies from large
cities. Within an urban population there is a large hetero-
geneity of diabetes prevalence depending on the socio-
economic stratum studied and sampling response rate.4
Prevalence of diabetes can vary depending on geography,
age, sex, and race/ethnicity status. Most of this increased
burden will occur in developing countries. Among the
possible reasons for this estimated increase are shifts
toward a modern Western lifestyle with high caloric diets,
decreased physical activity, and greater obesity.2
Candidate genes are very relevant to the area of clinical
pharmacology and studies have been carried out to identify
single nucleotide polymorphism (SNP) in candidate genes
that influence susceptibility to type 2 diabetes. The first
reported genome-wide association (GWA) scan implicated
variants at five susceptibility loci that include TCF7L2 and
novel loci near the genes SLC30A8 and IDEKI11-HHEX,
LOC387761, and EXT-ALX4.5 Three companion GWA studies
replicated evidence for PPARG, KCNJ11, TCF7L2, SLC30A8,
and IDE-K1F11, CDKN2A-CDKN2B, IGF2BP2, FTO, and a region
of chromosome 11with no annotated genes.6,7 Using SNP and
gene-based analysis methods replicated evidence for
PPARG, KCNJ11, and SLC 2A2; identified significant SNPs in
genes ENPP1 and NRF1 and implicated novel genes, including
RAPGEF1 and TP53 in type 2 diabetes susceptibility.1Figure 2 Agarose gel showing 1023C>A restriction frag-
ment length polymorphism. Lane 1 PUC 19 DNA/MspI digest
marker. Lane 2 Unrestricted product. Lanes 3, 5, 8 Samples
having wild type allele (CC). Lanes 4, 6, 7 Samples having
heterozygous allele (CA).Protein tyrosine phosphatase
The protein encoded by this gene is the founding member
of the protein tyrosine phosphatase (PTP) family, which was
isolated and identified based on its enzymatic activity and
amino acid sequence. PTPs catalyze the hydrolysis of the
phosphate monoesters, especially on tyrosine residues.
Members of the PT family share a highly conserved catalytic
motif, which is essential for the catalytic activity. PTPs are
known to be signaling molecules that regulate a variety of
cellular processes, including cell growth, differentiation,mitotic cycle, and oncogenic transformation. This PTP has
been shown to act as a negative regulator of insulin
signaling by dephosphorylating the phosphotyrosine resi-
dues of insulin receptor kinase. This PTP was also reported
to dephosphorylate epidermal growth factor receptor
kinase, as well as JAK 2 (Janus Kinase 2), TYK 2 (Tyrosine
Kinase 2), which implicated the role of this PTP in cell
growth control, and cell response to interferon
stimulation.8
PTP N1 gene polymorphism has been widely studied to
determine its association with type 2 diabetes in various
populations.9 However, the role of this gene has not yet
been studied in South Indian population. This study was
performed to determine the association between the allelic
polymorphism in protein tyrosine phosphatase N1 gene and
the occurrence of type 2 diabetes in a Thanjavur pop-
ulation, the representative of South Indian populations.Materials and methods
Study population
The present study included 192 individuals, including 96
nondiabetics as controls and 96 diabetics as cases, from
Thanjavur, Tamilnadu, India. Blood samples were obtained
from them with an overnight fast only after they were
informed about the purpose of the study. The patients
Table 1 Genotype distribution of the 1023C>A poly-
morphism among the local population.
Genotype Population
Case
(N Z 96)
Control
(N Z 96)
N % N %
CC 62 64 54 56
CA 16 17 20 21
AA 18 19 22 23
Table 3 Genotype frequency distribution.
Genotype Case Control Total c2 value p value Inference
Wild 62 54 116 1.393 3.84 Obeys
Null
Hypothesis
Variant 34 42 76
c2 Z Chi square.
96 D. Somasekharan, T. Arunachalamanswered a questionnaire regarding health, dietary pattern,
family history of diabetes and obesity, lifestyle features,
including physical activity, stress pattern, smoking habits,
and consumption of alcohol. Anthropometricmeasurements,
including height and weight, were measured for all partici-
pants. Body mass index (BMI) was calculated as kg/m2. The
participants were classified according to WHO classification
and BMI scores of<25 as lean,25 to<30 as overweight, and
>30 as obese.
Genotyping
A total of 5 ml of venous blood was drawn from each of the
individuals and genomic DNA was isolated by salting out
procedure.10 Polymerase chain reaction (PCR)eRFLP based
genotyping was carried out using gene-specific primers. The
primer toamplify the1023C>A regionwasdesignedusing the
Integrated DNA Technology (IDT, Medox Biotech India Private
Limited, Chennai, India) tool, forward primer 5’TAGCA-
GAAACCGAGTTTCACC3’, and 5’CCTGGGTAACAGAATCAGA
CC3’ reverse primer. PCR was performed in 20 ml reaction
volumewith 120 ng genomic DNA, 10 ml mastermix (dNTPmix,
PCR buffer, Taq polymerase), 1.5 ml of forward primer, and
2.5 ml of reserve primer, and was made using up to 20 ml of
steriledistilledwater. Thirty-four temperaturecycleswith the
annealing temperature of 58Cwere performed. Thedesigned
primers produced an amplified product size of 312 bp, which
was visualized in 1.6% agarose gel (Fig. 1).
The amplified products were restricted with the
restriction endonucleases Bcl 1. RFLP was performed with
10 ml of amplified DNA, 2.5 ml of restriction buffer, and
0.5 ml of restriction enzyme (Bcl1), and the reaction
mixture was made using up to 25 ml of sterile distilled
water. The reaction mixture was short-spinned for
complete mixing and incubated at an optimum temperatureTable 2 BMI based classification of a case control
population.
BMI
(kg/m2)
Case
(N Z 96)
Genotype Control
(N Z 96)
Genotype
CC CA AA CC CA AA
<25 26 9 6 11 40 20 13 7
<30 49 32 10 7 32 16 5 11
>30 21 21 d d 24 18 2 4
BMI Z body mass index.of 50C for an incubation time of 2-6 hours. It produced
a fragment size of 249 and 63 bp, which was visualized in
1.6% agarose gel (Fig. 2); the different genotypes were
identified from the band pattern.
Statistical analysis
A c2 test was performed for genotypic frequencies and to
make case-control comparisons for the polymorphisms
tested using the SPSS software.
Results
Genotype frequency indicates the most or least prevalent
genotype inapopulation.Thegenotypicdistributionandallele
frequency of the polymorphism tested in the PTPN1 gene for
type 2 diabetes are listed in Table 1.The frequency of occur-
renceofvariant alleleA, in thehomozygous formof1023C>A
polymorphism,was found tobe less (19%)whencomparedwith
the control population (Table 1). In the BMI-based classifica-
tion of case and control, variant allele A, in the homozygous
form of 1023C>A polymorphism, was absent in participants
with BMIs below 30, but it was present in four of the controls
withvariant allele (Table2).The genotypicdistribution for this
variant (1023C>A) was compared using the c2 test between
the group of participants, and it showed no statistical signifi-
cantdifferencebetweenthem(Table3).Hence,weconcluded
that the presence of A allele in the homozygous form of
1023C>Awas not a significant predictor of type 2 diabetes in
our studied sample.
Discussion
This study reports the relationship of PTPN1 polymorphisms
for the first time in type 2 diabetes populations in South India
(Thanjavur). From these gene disease association studies, it
was found that in the studied population, the 1023C>A
variation of PTPN1 gene shows no significant association with
type 2 diabetes since no statistical significant results were
obtained at 95% confidence interval. Our results follow the
studies done in Iranian11 and Canadian populations.12 Thus, it
can be speculated that there is no influence of the PTPN1
polymorphism on type 2 diabetes in the studied population.
Hence, it cannot be considered as a potential marker for type
2 diabetes. The resultsmay be validated by analyzing a larger
sample size in the future.
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